Hi

It's a marathon of clinical trials to get a new medicine approved and its worth it if MindBio's lead candidate MB22001 can prove more effective and without the side effects seen commonly in anti-depressant medications.

READ MORE

To date, the trial outcomes have been outstanding and the data stemming from Phase 1 RCTs and Phase 2A depression trials has even surprised me.

We have seen dramatic improvements in mood, sleep, anxiety, quality of life and anti-depressant effects sustained 6 months post an 8 week treatment cycle with MB22001.

This is the most advanced take-home use case of a psychedelic medicine entering late stage clinical trials and the mounting data looks more than promising.

A microdose of MB22001 is sub-hallucinogenic and can be taken by patients safely at home, and then they can get on with their day in the same way they would if they were taking any other medication.

We invite you to join us in support of creating a brighter future for mental health.

Stay Well!

JUSTIN HANKA

Chief Executive Officer & Co-Founder

MindBio Therapeutics Corp (Frankfurt: WF6), (CNSX: MBIO)

Discover More